Kardigan files for U.S. IPO to fund heart drug development

Investing.com -- Cardiovascular drug developer Kardigan filed Tuesday for an initial public offering in the United States.

The clinical-stage biotechnology company is developing precision medicines for cardiovascular diseases and is advancing three late-stage experimental therapies.

Kardigan will list on the Nasdaq Global Market under the ticker symbol KARD.

J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are the underwriters for the offering.

The filing comes as biotech IPO issuance rebounds, signaling improving risk appetite in equity markets as investors return to healthcare companies with advanced-stage drug pipelines and clearer paths toward commercialization.

You May Also Be Interested In

• Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report
• Saudi Arabia shuts East-West Pipeline after attacks
• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial